Movers of most recent trading session: Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP), Applied Genetic Technologies Corporation (NASDAQ:AGTC)

3d blue background with stock diagram

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP)

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) represented a move of 0 percent or $0.01 per share and closed its previous day trading session at $2.45. 0 Shares were traded in the last trading session with an Average Volume of 150.17 Million Shares. The stock currently has a Market Capitalization of 57.67 Million.

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company discovers and develops oral drug candidates to treat inflammation and cancer. Aquinox Pharmaceuticals, Inc. is headquartered in Vancouver, Canada.

The stock traded between $ 1.96 and $16.90 over 1-Year time period showing its price to sales ratio of 2.31. Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.

Right now, the stock has a 50-Day Simple Moving Average of $-3.63 and 200-Day Simple Moving Average of $-68.12. Its Price to Free Cash Flow is 0 and Price to Book of 0.75.

Analyst’s recommended the stock as 3 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) reported its Actual EPS of $-0.64/share. The analysts offering Earnings Estimates for the company were believing that Aquinox Pharmaceuticals, Inc. could bring EPS of $-0.21/share. The difference between Actual EPS and Estimated EPS was -0.43 Percent. Thus showing an Earnings Surprise of -204.8 Percent.

Applied Genetic Technologies Corporation (NASDAQ:AGTC)

In the last trading session, Applied Genetic Technologies Corporation (NASDAQ:AGTC) added its value by 0% closing at the price of $6.14. The stock currently has market capitalization of 111.38 Million, with average volume of 161.84 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Applied Genetic Technologies Corporation (NASDAQ:AGTC) is showing beta of 2.03. This particular value of beta suggests that Applied Genetic Technologies Corporation (NASDAQ:AGTC) has historically moved 203% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Applied Genetic Technologies Corporation (NASDAQ:AGTC) is at $-1.08.

The stock currently has RSI of 36.77. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) topped its 52-week high price of $7.50 on 10/01/18 and 52-Week Low Price of $3.45 on 12/18/17. The Stock currently has P/E (price to earnings ttm) of 0 and Weekly volatility of 4.23% and monthly volatility of 5.81% respectively.